Full Access
The therapy of respiratory chain encephalomyopathy: a critical review of the past and current perspective
U. A. Walker,
E. Byrne,
U. A. Walker
Melbourne Neuromuscular Research Centre, St. Vincent's Hospital Victoria, Australia.
Search for more papers by this authorCorresponding Author
E. Byrne
Melbourne Neuromuscular Research Centre, St. Vincent's Hospital Victoria, Australia.
E. Byrne, Melbourne Neuromuscular Research Centre, St. Vincent's Hospital Melbourne, 41 Victoria Pde, Melbourne Vic 3065, AustraliaSearch for more papers by this authorU. A. Walker,
E. Byrne,
U. A. Walker
Melbourne Neuromuscular Research Centre, St. Vincent's Hospital Victoria, Australia.
Search for more papers by this authorCorresponding Author
E. Byrne
Melbourne Neuromuscular Research Centre, St. Vincent's Hospital Victoria, Australia.
E. Byrne, Melbourne Neuromuscular Research Centre, St. Vincent's Hospital Melbourne, 41 Victoria Pde, Melbourne Vic 3065, AustraliaSearch for more papers by this authorAbstract
The mitochondrial respiratory chain encephalomyopathies represent an important group of multisystem disorders. No curative treatment is currently available. A number of measures have been reported to have a theoretical potential to improve respiratory function. These treatment strategies have variable scientific support, many reports being anecdotal. We critically review the various therapeutic measures employed and suggest future treatment directions.
References
- 1 Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemiosmotic type of mechanism. Nature 1961: 191: 144–148.
- 2 Soumalainen A, Kaukonen J, Amati P et al. An auto-somal dominant locus predisposing to deletions of mitochondrial DNA. Nat Genet 1995: 9: 146–151.
- 3 Bodnar AG, Cooper JM, Holt IJ, Leonard JV, Schapira AH. Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion. Am J Hum Genet 1993: 53: 663–669.
- 4 Poulton J, Morten K, Freeman-Emmerson C et al. Deficiency of the human mitochondrial transcription factor h-mtTFA in infantile mitochondrial myopathy is associated with mtDNA depletion. Hum Mol Genet 1994: 3: 1763–1769.
- 5 Kearns TP, Sayre GP. Retitinitis pigmentosa, external ophthalmoplegia and complete heart block. Arch Ophthalmol 1958: 60: 280–289.
- 6 Olsen W, Engel WK, Walsh GO, Einaugler R. Oculocraniosomatic neuromuscular disease with “ragged-red” fibres. Arch Neurol 1972: 26: 193–211.
- 7 Pavlakis SG, Phillips PC, DiMauro S. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes: a distinctive clinical syndrome. Ann Neurol 1984: 16: 481–488.
- 8 Fukuhara N, Tokihuchi N, Shirakawa K, Tsubaki T. Myoclonus epilepsy associated with red ragged fibres (mitochondrial abnormalities): disease entity or a syndrome? Light and electron microscopic studies of two cases and a review of the literature. J Neurol Sci 1980: 47: 117–133.
- 9 DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. [Review]. Arch Neurol 1993: 50: 1197–1208.
- 10 Wallace DC. Mitochondrial diseases: genotype versus phenotype. TIG 1993: 9: 128–133.
- 11 Walker UA, Jean-Francois B, Byrne E. The impact of the 25th chromosome on mitochondrial dysfunction in human disease. J Clin Neurosci 1995: 2: 107–117.
- 12 Linnane AW. Mitochondrial DNA mutation and the ageing process: bioenergy and pharmacological intervention. Mutat Res 1992: 275: 195–208.
- 13 Schneider H, Lemasters JJ, Hackenbrock CR. Lateral diffusion of ubiquinone during electron transfer in phospholipid and ubiquinone-enriched mitochondrial membranes. J Biol Chem 1982: 257: 10789–10793.
- 14 Landi L, Cabrini L, Sechi AM, Pasquali P. Antioxidative effect of ubiquinones on mitochondrial membranes. Biochem J 1984: 222: 463–466.
- 15 Ocasahara S, Engel A, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci USA 1989: 86: 2379–2382.
- 16 Ogasahara S, Yorifuji S, Nishikawa Y et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q 10 in Kearns-Sayre syndrome. Neurology 1985: 35: 372–377.
- 17 Nakamura T, Sanma H, Himeno M, Kato K. Transfer of exogenous coenzyme Q10 to the inner membrane of heart mitochondria in rats; in Y Yamamura, K Folkers, Y Ito, (eds): Biomedical and clinical aspects of coenzyme Q. Amsterdam , Elsevier, 1980, pp 3–14.
- 18 Zierz S, Von Wersebe O, Bleistein J, Jerusalem F. Exogenous coenzyme Q (CoQ) fails to increase CoQ in skeletal muscle of two patients with mitochondrial myopathies. J Neurol Sci 1990: 95: 283–290.
- 19 Bresolin N, Doriguzzi C, Ponzetto C et al. Ubide-carenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990: 100: 70–78.
- 20 Nishikawa Y, Takahashi M, Yorifuji S et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalo-myopathy with cytochrome c oxidase deficiency. A 31P NMR study. Neurology 1989: 39: 399–403.
- 21 Ogasahara S, Nishikawa Y, Yorifuji S et al. Treatment of Kearns-Sayre syndrome with coenzyme Q 10. Neurology 1986: 36: 45–53.
- 22 Bresolin N, Bet L, Binda A et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 1988: 38: 892–899.
- 23 Abe K, Fujimura H, Nishikawa Y et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991: 83: 356–359.
- 24 Bendahan D, Desnuelle C, Vanuxem D et al. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 1992: 42: 1203–1208.
- 25 Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. Proc Natl Acad Sci USA 1989: 86: 7952–7956.
- 26 Goda S, Hamada T, Ishimoto S, Kobayashi T, Goto I, Kuroiwa Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987: 234: 62–65.
- 27 Tranchant C, Mousson B, Mohr M et al. Cardiac transplantation in an incomplete Kearns-Sayre syndrome with mitochondrial DNA deletion. Neuromusc Disord 1993: 3: 561–566.
- 28 Matthews PM, Ford B, Dandurand RJ et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993: 43: 884–890.
- 29 Zierz S, Jahns G, Jerusalem F. Coenzyme Q in serum and muscle of 5 patients with Kearns-sayre syndrome and 12 patients with ophthalmoplegia plus. J Neurol 1989: 236: 97–101.
- 30 Barkworth MF, Dyde CJ, Johnson DKI, Schnelle K. An early phase I study to determine the tolerance, safety and pharmacokinetics of idebenone following multiple oral doses. Arzneim-Forsch 1985: 35: 1704–1707.
- 31 Suno M, Nacoaka A. Inhibition of lipid peroxidation by a novel compound, ibedenone (CV-2619). Jpn J Pharmacol 1984: 35: 196–198.
- 32 Sugiyama Y, Fujita T. Stimulation of respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism. FEBS Lett 1985: 184: 48–51.
- 33 Kawakami M, Itoh T. Effects of idebenone on monoamine metabolites in cerebrospinal fluid of patients with cerebro-vascular dementia. Arch Gerontol Geriatr 1989: 8: 343–353.
- 34 Yamazaki M, Igarashi H, Hamamoto M. Miyazaki T, Nonaka I. [A case of mitochondrial encephalomyopathy with schizophrenic psychosis, dementia and neuroleptic malignant syndrome]. [Japanese]. Rinsho Shinkeigaku 1991: 31: 1219–1223.
- 35 Ihara Y, Namba R, Kuroda S. Sato T, Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 1989: 90: 263–271.
- 36 Thierry MJ, Hermodson MA, Suttie JW. Vitamin K and warfarin distribution and metabolism in the warfarin-resistant rat. Am J Physiol 1970: 219: 854–859.
- 37 Marcus R, Coulston AM. Fat-soluble vitamins. Vitamins A, K, and E; in LS Goodman, A Gilman, (eds): The pharmacological basis of therapeutics. New York , Oxford , Beijing , Frankfurt , Sao Paulo , Sydney , Tokyo , Toronto , Pergamon Press, 1990, pp 1553–1571.
- 38 Nosoh Y. Kajioka J. Itoh M. Effect of menadione on the electron transport pathway of yeast mitochondria. Arch Biochem Biophys 1968: 127: 1–6.
- 39 Cooper JM, Hayes DJ, Challiss RA, Morgan-Hughes JA, Clark JB. Treatment of experimental NADH ubiquinone reductase deficiency with menadione. Brain 1992: 115: 991–1000.
- 40 Holland PC, Clark MG, Bloxham DP, Lardy HA. Mechanism of action of the hypoglycemic agent diphenyleneiodonium. J Biol Chem 1973; 248: 6050–6056.
- 41 DeGroot H, Noll T, Sies H. Oxygen dependence and subcellular partitioning of hepatic menadione-mediated oxygen uptake. Arch Biochem Biophys 1985: 243: 556–562.
- 42 Eleff S, Kennaway NG, Buist NRM et al. 31P-NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci USA 1984: 81: 3529–3533.
- 43 Argov Z, Bank WJ, Maris J et al. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: a 31P-NMR follow-up study. Ann Neurol 1986: 19: 598–602.
- 44 Lou HC. Correction of increased plasma pyruvate and plasma lactate levels using large doses of thiamine in patients with Kearns-Sayre syndrome. Arch Neurol 1981: 38: 469.
- 45 Mastalgia FL, Thompson PL, Papadimitriou JM. Mitochondrial myopathy, cardiomyopathy, lactic acidosis and response to prednisone and thiamine. Aust NZ J Med 1980: 10: 660–664.
- 46 Marcus R, Coulston AM. Water-soluble vitamins. The vitamin B complex and ascorbic acid: In: LS. Goodman A Gilman eds. The parmacological basis of therapeutics. Oxford : Pergamon Press, 1990: 1530–1552.
- 47 Addison R, McCormick D. Biogenesis of flavoprotein and cytochrome components in hepatic mitochondria from riboflavin deficient rats. Biochem Biophys Res Commun 1978: 81: 133–138.
- 48 Arts WFM, Scholte HR, Bogaard JM, Kerrebijn KF, Luyt-Houwen IEM. NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet 1983: i: 581–582.
- 49 Penn AM, Lee JW, Thuillier P et al. MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 3 1P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992: 42: 2147–2152.
- 50 Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. J Neurol Sci 1993: 118: 181–187.
- 51 Griebel V, Krageloh-Mann I, Ruitenbeek W, Trijbels JM, Paulus W. A mitochondrial myopathy in an infant with lactic acidosis. Dev Med Child Neurol 1990: 32: 528–531.
- 52 Gubbay SS, Hankey GJ, Tan NTS, Fry JM. Mitochondrial encephalomyopathy with corticosteroid dependence. Med J Aust 1989: 151: 100–108.
- 53 Shapira Y, Harel S, Russell A. Mitochondrial encephalomyopathies; a group of neuroniuscular disorders with defects in oxidative metabolism. Isr J Med Sci 1977; 13: 161–164.
- 54 Montagna P, Gallassi R, Medori R et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 1988: 38: 751–754.
- 55 Fox C. Dunne J. Corticosteroid responsive mitochondrial encephalomyopathy [letter]. Aust NZ J Med 1993: 23: 522–523.
- 56 Peterson PL, Martens M, Lee C-P. The treatment of mitochondrial disease. Neurology 1986: 36 Suppl.1: 95.
- 57 Curless RG, Bachynski B, Gregorios JB, Benke P, Cullen R. Fatal metabolic acidosis, hyperglycemia, and coma after steroid therapy for Kearns-Sayre syndrome. Neurology 1986: 36: 872–873.
- 58 Goodman MN, Ruderman NB, Aoki TT. Glucose and amino acid metabolism in perfused skeletal muscle – effect of dichloroacetate. Diabetes 1978: 27: 1065–1074.
- 59 McAllister A, Allison SP, Randle PJ. Effects of dichloroacetate on the metabolism of glucose, pyruvate, acetate, 3-hydroxybutyrate and palmitate in rat diaphragm and heart muscle in vitro and on extraction of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo. Biochem J 1973: 134: 1067–1081.
- 60 Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, Misbin RI. Treatment of lactic acidosis with dichloroacetate. NEJM 1983: 309: 390–396.
- 61 Stacpoole PW, Lorenz A, Thomas RG, Harman EM. Dichloroacetate in the treatment of lactic acidosis. Ann Int Med 1988: 108: 58–63.
- 62 Stacpoole PW, Wright EC, Baumgartner TG et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis. NEJM 1992: 327: 1564–1569.
- 63 Saijo T, Naito E, Ito M, Takeda E, Hashimoto T, Kuroda Y. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics 1991: 22: 166–167.
- 64 Marconi C, Sassi G, Cerretelli P. The effect of an alpha-ketoglutarate-pyridoxine complex on human maximal aerobic and anaerobic performance. Eur J Appl Physiol 1982: 49: 307–317.
- 65 Kobayashi M, Morishita H, Okajima K, et al. Successful treatment with succinate supplement in a patient with a deficiency of complex I (NADH-CoQ reductase) (abstract). The Fourth International Congress of Inborn Errors of Metabolism, Sendai, Japan 1987: 148.
- 66 Luft R, Ikkos D, Palmieri G. Ernster L, Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: A correlated clinical, biochemical, and morphological study. J Clin Invest 1962: 41: 1776–1804.
- 67 DiMauro S, Bonilla E, Lee CP et al. Luft's disease. Further biochemical and ultrastructural studies of skeletal muscle in the second case. J Neurol Sci 1976: 27: 217–232.
- 68 Ichiki T. Tanaka M, Nishikimi M et al. Deficiency of subunits of complex I and mitochondrial encephalomyopathy. Ann Neurol 1988: 23: 287–294.
- 69 Ooiwa Y, Uematsu Y, Terada T et al. Cerebral blood flow in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Stroke 1993: 24: 304–309.
- 70 Channer KS, Channer JL, Campbell MJ, Rees JR. Cardiomyopathy in the Kearns-Sayre syndrome. Br Heart J 1988: 59: 486–490.
- 71 Lauwers MH, Van Lersberghe C, Camu F. Inhalation anaesthesia and the Kearns-Sayre syndrome. Anaesthesia 1994: 49: 876–878.
- 72 Barohn RJ, Clanton T, Sahenk Z, Mendell JR. Recurrent respiratory insufficiency and depressed ventilatory drive complicating mitochondrial myopathies. Neurology 1990: 40: 103–106.
- 73 Van Loon APGM, Brandli AW, Schatz G. The presequences of two imported mitochondrial proteins contain information for intracellular and intramitochondrial sorting. Cell 1986: 44: 801–812.
- 74 Vestweber D, Schatz G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 1989: 338: 170–172.
- 75 Karpati G, Ascadi G. The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases. Muscle Nerve 1993: 16: 1141–1153.
- 76 Naffakh N, Pinset C, Montarras D, Pastoret C, Danos O, Heard JM. Transplantation of adult-derived my-oblasts in mice following gene transfer. Neuromusc Disord 1993: 3: 413–417.
- 77 Michael SI, Curiel DT. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Therapy 1994: 1: 223–232.
